A Phase 3 interventional study of Etrasimod and Placebo in Moderately to Severely Active Ulcerative Colitis, sponsored by Everstar Therapeutics Limited. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-09.
Sponsored by Everstar Therapeutics Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.
Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 4th largest by enrollment, is one of 3 that started in 2019, is one of 5 in phase 3, and was the 6th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, Canada and 7 more countries
Ages 2–11
Pfizer · Sites in United States, Japan, Poland and 2 more countries
Ages 12–17
Sir Run Run Shaw Hospital
Ages 18–100
By country, each count listing its studies:
etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2019.
This study's enrollment of 341 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 195 across the 12 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 4 most frequent:
This is the only study on the registry with Everstar Therapeutics Limited as lead sponsor.
Everstar Therapeutics Limited has 1 study filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
1 of the studies testing etrasimod in Colitis, Ulcerative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07782242Sir Run Run Shaw HospitalComaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UC | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing etrasimod in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.
Condition or disease: Ulcerative Colitis Intervention/treatment: Drug: Etrasimod Drug: Placebo Phase: Phase 3
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
2mg/tablet, administratered orally, once daily
Drug: Etrasimod
matching tablet, administratered orally, once daily
Drug: Placebo
2mg/tablet, administratered orally, once daily
Drug: Etrasimod
Drug:Etrasimod Tablet other name:APD334
Drug:placebo Tablet
Proportion of Subjects With Clinical Remission Assessed by modified Mayo score(mMS)
Clinical remission per mMS(endoscopy, rectal bleeding, stool frequency), ranging from 0-9 (normal to severe)
Time frame: induction period week 12
Proportion of Subjects With Clinical Remission Assessed by modified Mayo score(mMS)
Clinical remission per mMS, ranging from 0-9 (normal to severe)
Time frame: Maintenance period week 40
Proportion of Subjects Achieving Endoscopic Improvement Assessed by endoscopic subscore
Endoscopic improvement per endoscopy subscore, ranging from 0 to 3 (normal to severe)
Time frame: induction period week 12
Proportion of Subjects with Clinical Response Assessed by modified Mayo score(mMS)
Clinical response per mMS, ranging from 0 to 9 (normal to severe).
Time frame: induction period Week 12
Proportion of Subjects Achieving Endoscopic Improvement Assessed by endoscopic subscore
Endoscopic improvement per endoscopy subscore, ranging from 0 to 3 (normal to severe)
Time frame: Maintenance period Week 40
Proportion of Subjects with Clinical Response Assessed by modified Mayo score(mMS)
Clinical response per mMS, ranging from 0 to 9 (normal to severe)
Time frame: Maintenance period Week 40
Proportion of Subjects who achieve symptomatic response over time
Symptomatic response per paritial Mayo score(rectal bleeding, stool frequency), ranging from 0-6(normal to severe)
Time frame: Open label treatment period up to 40 Weeks
Proportion of Subjects who achieve Symptomatic Remission over time
Symptomatic remission per paritial Mayo score, ranging from 0-6(normal to severe)
Time frame: Open label treatment period up to 40 Weeks
Started Sep 2019 (actual). Primary completion is estimated for Jul 2024, 58 months after the start.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 58 months is above that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrasimod